Увійти

Готові списки джерел за темами / Lymphomas and leukemias

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Lymphomas and leukemias"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Lymphomas and leukemias".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Lymphomas and leukemias"

1

Radich, Jerald P., Andrew D. Zelenetz, Wing C. Chan, et al. "NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas." Journal of the National Comprehensive Cancer Network 7, Suppl_4 (2009): S—1—S—34. http://dx.doi.org/10.6004/jnccn.2009.0077.

Повний текст джерела

Анотація:

The introduction of targeted therapies has revolutionized treatment and improved outcomes in patients with leukemias and lymphomas. However, many patients experience relapse caused by the persistence of residual malignant cells. Cytogenetic and molecular techniques are increasingly being used to assess and quantify minimal residual disease (MRD). The emergence of advanced technologies has led to the discovery of multiple novel molecular markers that can be used to detect MRD and predict outcome in patients with leukemias and lymphomas. Gene expression signatures that predict clinical outcomes

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Dunphy, Cherie H. "Gene Expression Profiling Data in Lymphoma and Leukemia: Review of the Literature and Extrapolation of Pertinent Clinical Applications." Archives of Pathology & Laboratory Medicine 130, no. 4 (2006): 483–520. http://dx.doi.org/10.5858/2006-130-483-gepdil.

Повний текст джерела

Анотація:

Abstract Context.—Gene expression (GE) analyses using microarrays have become an important part of biomedical and clinical research in hematolymphoid malignancies. However, the methods are time-consuming and costly for routine clinical practice. Objectives.—To review the literature regarding GE data that may provide important information regarding pathogenesis and that may be extrapolated for use in diagnosing and prognosticating lymphomas and leukemias; to present GE findings in Hodgkin and non-Hodgkin lymphomas, acute leukemias, and chronic myeloid leukemia in detail; and to summarize the pr

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Rosolen, A., M. Nakanishi, DG Poplack, et al. "Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies." Blood 73, no. 7 (1989): 1968–72. http://dx.doi.org/10.1182/blood.v73.7.1968.1968.

Повний текст джерела

Анотація:

Abstract The expression of the interleukin-2 (IL-2) receptor was studied in neoplastic cells derived from acute leukemias, T-cell lymphoblastic lymphomas, peripheral T-cell lymphomas, chronic lymphocytic leukemias, well-differentiated lymphocytic lymphomas, and established cell lines by both flow cytometric analysis and sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) after affinity crosslinking of radiolabeled IL-2. Cells from most acute leukemias (19 of 22), irrespective of their subtype (T, common or nonlymphoid leukemias), as well as T-cell lymphoblastic lymphomas and p

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Rosolen, A., M. Nakanishi, DG Poplack, et al. "Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies." Blood 73, no. 7 (1989): 1968–72. http://dx.doi.org/10.1182/blood.v73.7.1968.bloodjournal7371968.

Повний текст джерела

Анотація:

The expression of the interleukin-2 (IL-2) receptor was studied in neoplastic cells derived from acute leukemias, T-cell lymphoblastic lymphomas, peripheral T-cell lymphomas, chronic lymphocytic leukemias, well-differentiated lymphocytic lymphomas, and established cell lines by both flow cytometric analysis and sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) after affinity crosslinking of radiolabeled IL-2. Cells from most acute leukemias (19 of 22), irrespective of their subtype (T, common or nonlymphoid leukemias), as well as T-cell lymphoblastic lymphomas and peripheral

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Carbone, A., A. Gloghini, V. Zagonel, et al. "The expression of CD26 and CD40 ligand is mutually exclusive in human T- cell non-Hodgkin's lymphomas/leukemias." Blood 86, no. 12 (1995): 4617–26. http://dx.doi.org/10.1182/blood.v86.12.4617.bloodjournal86124617.

Повний текст джерела

Анотація:

CD26 and CD40 ligand (CD40L) are surface molecules on human activated T lymphocytes that play a critical role in the regulation of lymphopoiesis. Both molecules are expressed on a restricted fraction of human T-cell non-Hodgkin's lymphomas (NHL)/leukemias; however, little is known about their functional and/or clinical significance in these disorders. In this study, the pattern of expression of CD40L was compared with that of the CD26 molecule. A series of 67 human T-cell NHL/leukemias and a panel of leukemia/lymphoma T-cell lines were evaluated by immunohistochemistry, flow cytometry, and RNA

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Poon, Eileen Yi Ling, Evelyn Wong, Wei Lin Goh, et al. "Hematological malignancies in the adolescent and young adult (AYA) population in Singapore." Journal of Clinical Oncology 38, no. 15_suppl (2020): e13630-e13630. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e13630.

Повний текст джерела

Анотація:

e13630 Background: Hematological malignancies is thought to be one of the more common Adolescent and Young Adult (AYA) cancers and constitute leukemias and lymphomas. However, little is known about its incidence and prevalence in Asia. We also do not have any data on its behavior or its prognosticators. The outcomes of this group of patients is also unknown when compared to the pediatrics or geriatrics, but is expected to be not as ideal. There is no consensus on whether this group of patients should be treated as pediatrics or as the older adults. We have sought to evaluate the prevalence and

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Schwarzinger, Ilse, Markus Exner, Harald Esterbauer, et al. "Microvessel Endothelial Cells of Hematological Malignancies Harbor Disease Specific Genetic Aberrations." Blood 104, no. 11 (2004): 544. http://dx.doi.org/10.1182/blood.v104.11.544.544.

Повний текст джерела

Анотація:

Abstract The growth of most tumors depends on the formation of new blood vessels. In contrast to genetically unstable tumor cells, endothelial cells of tumor vessels are believed to be normal diploid cells that do not acquire mutations. We have recently observed that microvessel endothelial cells of patients with B-cell lymphomas carry lymphoma specific aberrations (NEJM351:250–9, 2004). The aim of this study was to determine whether hematological malignancies other than B-cell lymphomas also carry disease specific genetic aberrations. Using a combined immunohistochemical and fluorescence in s

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Agrelo, Ruben, Fernando Setien, Jesus Espada, et al. "Inactivation of the Lamin A/C Gene by CpG Island Promoter Hypermethylation in Hematologic Malignancies, and Its Association With Poor Survival in Nodal Diffuse Large B-Cell Lymphoma." Journal of Clinical Oncology 23, no. 17 (2005): 3940–47. http://dx.doi.org/10.1200/jco.2005.11.650.

Повний текст джерела

Анотація:

Purpose Lamins support the nuclear envelope and provide anchorage sites for chromatin, but they are also involved in DNA synthesis, transcription, and apoptosis. Although the lack of expression of A-type lamins in lymphoma and leukemia has been reported, the mechanism was unknown. We investigated the possible role of CpG island hypermethylation in lamin A/C silencing and its prognostic relevance. Patients and Methods The promoter CpG island methylation status of the lamin A/C gene, encoding the A-type lamins, was analyzed by bisulfite genomic sequencing and methylation-specific polymerase chai

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Wang, Wei, Magdalena Czader, and Sa A. Wang. "Blood- and bone marrow–based mature T-cell and natural killer cell leukemias and lymphomas: a summary in the series of the 2023 SH/EAHP Workshop." American Journal of Clinical Pathology 164, no. 1 (2025): 7–25. https://doi.org/10.1093/ajcp/aqaf009.

Повний текст джерела

Анотація:

Abstract This session included 51 cases submitted to the workshop “Progress in T- and NK-cell Lymphomas and Leukemias” by the Society for Hematopathology and European Association for Haematopathology under “Blood/Bone Marrow–Based Mature T- and NK-Cell Leukemias/Lymphomas” or “T/NK-cell neoplasms with a Leukemic Presentation.” Entities encompassed T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia (LGLL), natural killer (NK)-LGLL/chronic lymphoproliferative disorder of NK cells, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, and their mimics. Submitted cas

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Rodrigues, Paulo Henrique Silva, Cybelle Façanha Barreto Medeiros Linard, Francisco José Maia Pinto, Rafaela de Lima Gomes Soares, Germison Silva Lopes, and Henrique Girão Martins. "The role of chemotherapy toxicity scales in decision-making for acute leukemia and lymphoma: a scoping review." Concilium 23, no. 18 (2023): 59–78. http://dx.doi.org/10.53660/clm-1979-23n49.

Повний текст джерела

Анотація:

Acute leukemias and non-Hodgkin lymphomas together rank 4th among the most common neoplasms. With curative treatment options, even in adverse situations, however, the decision-making process is delicate and statistical models can help. To identify the chemotherapy toxicity scales and their role in decision-making for the treatment of patients with acute lymphomas and leukemias, we conducted a scoping review on the PUBMED, BIREME, COCHRANE, and CAPES journal data platforms. Thirty articles were selected using the PRISMA protocol approach. There is no ideal scale for assessing chemotherapy toxic

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Lymphomas and leukemias"

1

Sandhu, Sukhinder K. "ROLE OF MICRORNA-155 IN B-CELL LEUKEMIAS/LYMPHOMAS." The Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1312400705.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Walsh, Sarah. "Analysis of Immunoglobulin Genes and Telomeres in B cell Lymphomas and Leukemias." Doctoral thesis, Uppsala University, Department of Genetics and Pathology, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5748.

Повний текст джерела

Анотація:

<p>B cell lymphomas and leukemias are heterogeneous tumors with different cellular origins. Analysis of immunoglobulin (Ig) genes enables insight into the B cell progenitor, as Ig somatic hypermutation correlates with antigen-related B cell transit through the germinal center (GC). Also, restricted Ig variable heavy chain (V<sub>H</sub>) gene repertoires in B cell malignancies could imply antigen selection during tumorigenesis. The length of telomeres has been shown to differ between GC B cells and pre/post-GC B cells, possibly representing an alternative angle to investigate B cell tumor orig

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Walsh, Sarah H. "Analysis of immunoglobulin genes and telomeres in B cell lymphomas and leukemias /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5748.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Kwok, Suet-kei Gladys. "The effectiveness of a chemotherapy educational programme (CEP) for Leukaemia and Lymphoma patients." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31972937.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Chan, Wai. "Clonal rearrangement of T-cell receptor delta gene in hematological malignancies and applications in detection of minimal residual disease /." Hong Kong : University of Hong Kong, 1995. http://sunzi.lib.hku.hk/hkuto/record.jsp?B1705512X.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Hovhannisyan, Narinée. "[18F] Fludarabine pour l'imagerie TEP des lymphomes." Thesis, Normandie, 2018. http://www.theses.fr/2018NORMC412/document.

Повний текст джерела

Анотація:

Bien que l’utilité de la TEP au [18F]FDG soit confirmée pour le diagnostic et le suivi thérapeutique chez les patients atteints de lymphome, la spécificité de la captation du [18F]FDG a été mise en doute en raison de sa dépendance au métabolisme du glucose, qui peut augmenter dans des conditions bégnines comme les processus inflammatoire ou infectieux. Compte tenu de ces limites, un nucléoside a été développé en tant que nouvel outil pour l'imagerie TEP ([18F]fludarabine). Une radiosynthèse entièrement automatisée a été mise en place et des études précliniques ont été menées sur des modèles mu

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Bejai, Prashanth. "Higher order spectra for the discrimination of malignant lymphomas and leukemia." Ohio : Ohio University, 2005. http://www.ohiolink.edu/etd/view.cgi?ohiou1113334700.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

黃傑煇 and Kit-fai Wong. "CD56-positive: natural killer cell lymphoma/leukaemia." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2001. http://hub.hku.hk/bib/B3198177X.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Wong, Kit-fai. "CD56-positive natural killer cell lymphoma/leukaemia /." Hong Kong : University of Hong Kong, 2001. http://sunzi.lib.hku.hk/hkuto/record.jsp?B23736197.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Cleary, Helen Julia. "Genetic analyses of radiation-induced leukaemias/lymphomas." Thesis, Brunel University, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.324649.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Lymphomas and leukemias"

1

Mughal, Tariq I. Understanding leukemias, lymphomas, and myelomas. Taylor & Francis, 2006.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

H, Wiernik Peter, ed. Leukemias and lymphomas. Churchill Livingstone, 1985.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Schiller, Gary J. Chronic Leukemias and Lymphomas. Humana Press, 2002. http://dx.doi.org/10.1385/1592593089.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Schiller, Gary J., ed. Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

J, Schiller Gary, ed. Chronic leukemias and lymphomas: Biology, pathophysiology, and clinical management. Humana Press, 2003.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

name, No. Chronic leukemias and lymphomas: Biology, pathophysiology, and clinical management. Humana Press, 2002.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

1946-, Cheson Bruce D., ed. Chronic lymphoid leukemias. 2nd ed. Marcel Dekker, 2001.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Bennett, John M., and Kenneth A. Foon, eds. Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias. Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-1713-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

1933-, Bennett John M., and Foon Kenneth A, eds. Immunologic approaches to the classification and management of lymphomas and leukemias. Kluwer Academic Publishers, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Kaspers, G. J. L., 1963-, ed. Innovative leukemia and lymphoma therapy. Informa Healthcare, 2008.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Lymphomas and leukemias"

1

Rai, Kanti R., and Niraj Gupta. "Chronic Leukemias." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Rosen, Peter J., and Jonathan Said. "Prolymphocytic Leukemias." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Schulz, Wolfgang A. "Leukemias and Lymphomas." In Molecular Biology of Human Cancers. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-16286-2_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Bociek, R. Gregory, and James O. Armitage. "Aggressive Large-Cell Lymphomas." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Horwitz, Steven M., and Sandra J. Horning. "Hodgkin’s Disease." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Wentworth, Nicole, and Alan Saven. "Hairy Cell Leukemia." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Pinter-Brown, Lauren C. "Sézary Syndrome." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Cavenagh, Jamie D., and T. Andrew Lister. "Chronic Lymphocytic Leukemia." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Sjak-Shie, Nelida N., and Gary J. Schiller. "Myeloproliferative Syndromes." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Emmanouilides, Christos. "Low-Grade Lymphoma." In Chronic Leukemias and Lymphomas. Humana Press, 2003. https://doi.org/10.1007/978-1-59259-308-8_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Lymphomas and leukemias"

1

Gorski, J., L. Van Hove, F. Vanlangendonck, M. A. Boogaerts, R. L. Verwilghen, and J. Vermylen. "PLATELET MEMBRANE GLYCOPROTEINS ABNORMALITIES IN PATIENTS WITH ACUTE LEUKEMIAS AND MALIGNANT LYMPHOMAS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643201.

Повний текст джерела

Анотація:

Membrane glycoproteins are implicated in platelet functions.In myeloproliferative disorders some of the platelet functions are known to be perturbated and an abnormal glycoproteins pattern was demonstrated ear-lier.In this study flow cytometry analysis of human platelet membrane glycoproteins IIa and IIIa in patients with acute leukemias and malignant lymphomas has been performed using monoclonal antibodies against these glycoproteins.A reduction in number of glycoproteins receptors on platelet membrane was demonstrated in patients with acute leukemias and malignant lymphomas in comparison wit

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Lopusna, Katarina, Pawel Nowialis, Staci L. Haney, Ajay Abraham, Jana Opavska, and Rene Opavsky. "Abstract 4339: Critical role of Dnmt3b catalytic activity in prevention of oncogene-induced leukemias and lymphomas." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4339.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Lopusna, Katarina, Pawel Nowialis, Staci L. Haney, Ajay Abraham, Jana Opavska, and Rene Opavsky. "Abstract 4339: Critical role of Dnmt3b catalytic activity in prevention of oncogene-induced leukemias and lymphomas." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4339.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Rossi, Edmund, Diane Rossi, Thomas Cardillo та ін. "Abstract 1803: HLA-DR-targeting tetrameric IFNα2b immunocytokine has potentin vitroandin vivoactivity in myelomas, lymphomas and leukemias". У Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1803.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Silva, Tarcisio Rubens da, Marina Monteiro Navarro, Mylena Mendes Hóstio, and Catherine Sonaly Ferreira Martins. "Case report - Ataxia-telangiectasia: innate error of immunity and neurological aspects." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.233.

Повний текст джерела

Анотація:

Introduction: Among more than 350 immunological deficiencies, 25% have neurological manifestations. Thus, Ataxia-telangiectasia stands out, being considered a combined immunodeficiency. In childhood, cerebellar motor findings and recurrent sinopulmonary infections, signaling early cerebellar degeneration and deficit in the combined immune response. It has an autosomal recessive inheritance pattern. Case report: She describes herself as a female patient, 9 years old, daughter of consanguineous parents and born in Sousa, Paraíba. In the child’s neuropsychomotor development, she sat down at 5 mon

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Stewart, Jessica A., and Ashok S. Bhagwat. "Abstract A14: Detection of a biomarker for B-cell non-Hodgkin lymphomas or leukemias using circulating tumor DNA without the use of PCR or next-gen sequencing." In Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-a14.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Morell Hita, J. L., R. Mazzucchelli, E. Perez Fernandez, et al. "SAT0141 Trends in the incidence of lymphomas and leukemias in patients with rheumatoid arthritis in spain: an observational cohort study of hospital discharges from 1999 to 2015 (TREND-AR STUDY)." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.4831.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Dražić, Branka, Mirjana Antonijević Nikolić, Vojislav Stanić, Vesna Stojiljković, and Slađana Tanasković. "CYTOTOXIC ACTIVITY OF AMINOCARBOXYLATEMACROCYCLIC Cu(II) COMPLEXES." In 17th International Conference on Fundamental and Applied Aspects of Physical Chemistry. Society of Physical Chemists of Serbia, 2024. https://doi.org/10.46793/phys.chem24ii.577d.

Повний текст джерела

Анотація:

Five binuclear complexes with general formula [Cu2(L)tpmc](ClO4)4, L= valine (1), norvaline (2) leucine (3), norleucine (4) and isoleucine (5) were tested in vitro against human tumor cell lines: THP-1 (human acute monocytic leukemic cell line), Jurkat (human acute T cell leukemia) and Ramos (B cells, Burkitt’s lymphoma cell line). The values of IC50 were calculated. All tested complexes showed significant activity against the tested lines. Complex 2 has promoted significant decreases in the metabolic activity of all three cell lines, especially according to Ramos (IC50 value is 40.21 ± 1.45 µ

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Moskalets, O. V. "Anti-rituximab antibodies in refractory / relapsing cases of chronic lymphocytic leukemia." In General question of world science. L-Journal, 2020. http://dx.doi.org/10.18411/gq-30-11-2020-02.

Повний текст джерела

Анотація:

Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, is widley used for treatment of lymphomas, rheumatologic diseases and other – 8 – General question of world science disorders. It is known that many monoclonal antibodies such as rituximab can elicit anti-drug antibodies, which may interfere with therapeutic response. The aim of this study was to investigate the incidence of antibodies to rituximab in patients with chronic lymphocytic leukemia. Serum concentrations of anti-rituximab antibodies was determined in blood serum of patients with B-chronic lymphocy

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Al Sharifi, Liqaa, Haider Abdul Ridha, Ahmed Rashid, Sinan Muhsin, and Teeb Jaafer. "Role of CD200 and CD43 in Diagnosis and Prognosis of CLL and NHL Patients." In 5th International Conference on Biomedical and Health Sciences. Cihan University-Erbil, 2024. http://dx.doi.org/10.24086/biohs2024/paper.1403.

Повний текст джерела

Анотація:

Background: Chronic lymphoproliferative disorder (LPD), is a malignant disease of lymphocytes in the blood and lymphatic tissue. Chronic lymphocytic leukaemia, it is the commonest type of chronic lymphoproliferative disorder. Scoring by immunophenotyping is used to differentiate B-cell chronic lymphocytic leukemia from other B-Non-Hodgkin lymphomas. CD200 (OX2) is a glycoprotein of membrane, it is related to type I superfamily of immunoglobulin . CD43 (Sialophorin) is a sialoglycoprotein that is present on the surface of T lymphocytes, some B lymphocytes, granulocytes and monocytes, that play

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Lymphomas and leukemias"

1

Iqbal, Fatiha. Chimeric Antigen Receptor (CAR) T Cell Immunotherapies for Leukemias and Lymphomas. Iowa State University, 2019. http://dx.doi.org/10.31274/cc-20240624-354.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Cooper, Laurence, and Rita Young. Development of Augmented Leukemia/Lymphoma-Specific T-Cell Immunotherapy for Deployment with Haploidentical, Hematompoietic Progenitor-Cell Transplant. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada487262.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Cooper, Laurence. Development of Augmented Leukemia/Lymphoma-Specific T-Cell Immunotherapy for Deployment with Haploidentical, Hematompoietic Progenitor-Cell Transplant. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada560655.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!